$7.28−0.12 (−1.62%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Maravai LifeSciences Holdings (MRVI) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
4 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 79% below its peak, net margin −70.4%.
The four lines that matter · FY21–FY25
Revenue ($M)▼28.3%
185.7
FY21→FY25CAGR −30.6%/yr
Net income ($M)▲9.7%
−130.8
one-off year: see footnoteCAGR —
Free cash flow ($M)▼218.7%
−70.7
FY21→FY25CAGR —
Diluted EPS▲14.3%
−0.90
buyback-liftedCAGR —
What the receipts whisper · what a headline number hides
Share count
−44.0%
257.8mn → 144.4mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$13.1M
−55.7% YoY in FY25 · 7.1% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-70¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin -70.4% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 212,996.0 | 185,743.0 | 259,185.0 | 288,945.0 | 883,001.0 | 799,240.0 | ▼28.3% | −30.6% |
Cost of revenue | 129,611.0 | 151,753.0 | 150,876.0 | 148,743.0 | 168,957.0 | 140,561.0 | ▲0.6% | +1.9% |
Gross profit | 83,385.0 | 33,990.0 | 108,309.0 | 140,202.0 | —A | —A | ▼68.6% | −50.8% |
Research & development | 14,769.0 | 17,402.0 | 19,221.0 | 17,280.0 | 18,369.0 | 15,219.0 | ▼9.5% | +3.4% |
Selling, general & admin | 123,047.0 | 145,118.0 | 161,771.0 | 151,390.0 | 129,259.0 | 100,064.0 | ▼10.3% | +9.7% |
Total operating expenses | 180,046.0 | 249,256.0 | 343,926.0 | 171,850.0 | 139,828.0 | 104,034.0 | ▼27.5% | +24.4% |
Operating incomefeeds ROC rank | −96,661.0 | −215,266.0 | −235,617.0 | −31,648.0 | 574,216.0 | 554,645.0 | ▲8.6% | — |
Other income, net | −18,753.0 | −19,708.0 | −25,865.0 | 649,384.0 | −22,744.0 | −23,880.0 | — | — |
Pretax income | −115,414.0 | −234,974.0 | −261,482.0 | 617,736.0 | 551,472.0 | 530,765.0 | ▲10.1% | — |
Income tax | −391.0 | −4,212.0 | −1,860.0 | 756,111.0 | 60,809.0 | 61,515.0 | ▼126.5% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −65,669.0 | −130,773.0 | −144,846.0 | −119,029.0 | 220,205.0 | 469,250.0 | ▲9.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.43 | −0.90 | −1.05 | −0.90 | 1.67 | 1.56 | ▲14.3% | — |
Diluted shares (mn) | 149.07 | 144.36 | 137.91 | 131.92 | 255.32 | 257.80 | ▲4.7% | −13.5% |
| Margins | ||||||||
Gross margin20th pct in Healthcare | 39.1% | 18.3% | 41.8% | 48.5% | —A | —A | ▼23.5pp | −30.2pp |
Operating margin | −45.4% | −115.9% | −90.9% | −11.0% | 65.0% | 69.4% | ▼25.0pp | −185.3pp |
Net margin19th pct in Healthcare | −30.8% | −70.4% | −55.9% | −41.2% | 24.9% | 58.7% | ▼14.5pp | −129.1pp |
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was 122% vs a 11% norm for this window, likely a one-time item; see the filing.FY24 effective tax rate was 1% vs a 11% norm for this window, likely a one-time item; see the filing.A Withheld: this year's gross margin is not on the same cost basis as the earlier years.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Maravai LifeSciences Holdings' revenue last fiscal year?
Maravai LifeSciences Holdings reported revenue of $185.7M in fiscal 2025, down 28.3% from fiscal 2024.
What was Maravai LifeSciences Holdings' net income?
Maravai LifeSciences Holdings reported net income of −$130.8M in fiscal 2025, a net margin of −70.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

